Second-Generation AR-Targeting Agent Explored in High-Risk Prostate Cancer

Tony Berberabe, MPH @OncBiz_Wiz
Published: Wednesday, Jun 15, 2016
Howard M. Sandler, MD

Howard M. Sandler, MD

Researchers are hoping the results of a latestage efficacy and safety study of apalutamide (ARN-509) in patients with high-risk, localized, or locally advanced prostate cancer who are receiving primary radiation therapy will demonstrate an improvement in metastasis-free survival, according to global principal investigator, Howard M. Sandler, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication